Analytical Data
-
Gene name
Semaphorin-4B/SEMA4B
- Application
-
Alternative Names
SEMAC; SEMC; Sema Domain, Transmembrane Domain And Cytoplasmic Domain Protein 4B
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q62179
-
Expression Region
Leu31~Pro240
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TMIGD2, or T-cell membrane immunoglobulin and mucin domain-containing protein 2, is a member of the immunoglobulin superfamily and plays a crucial role in immune regulation and cellular signaling. The discovery of TMIGD2 has drawn attention due to its potential implications in various diseases, particularly in cancer and autoimmune disorders. Studies have indicated that TMIGD2 is involved in modulating T-cell activation, influencing the immune response, and potentially serving as a therapeutic target. Recent research has focused on the characterization of recombinant TMIGD2 proteins to better understand their structure, function, and interactions with other cellular components. By expressing TMIGD2 in heterologous systems, researchers aim to produce sufficient quantities of the protein for functional assays, antibody generation, and structural studies. This recombinant approach not only facilitates the detailed investigation of TMIGD2’s role in immune modulation but also opens up possibilities for developing novel immunotherapeutic strategies. The growing interest in TMIGD2 highlights the necessity for comprehensive studies to elucidate its biology and therapeutic potential, paving the way for innovative treatments for immune-related diseases. Overall, the exploration of TMIGD2 recombinant proteins signifies an important step in understanding immune system dynamics and overcoming challenges in immunotherapy.
